Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02225366 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Injections of LL37 for Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02225366: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02225366 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02225366, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the appropriate dose of LL37 that can be given to patients with melanoma. Researchers also want to learn if LL37 can stimulate the immune system to help control the disease.
Interventions
- OTHER Photographs
- BIOLOGICAL LL37
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2020-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02225366
The ClinicalTrials.gov registry entry for NCT02225366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Photographs is the first listed.
NCT02225366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02225366 about?
NCT02225366 is a clinical study titled "Intratumoral Injections of LL37 for Melanoma". The goal of this clinical research study is to find the appropriate dose of LL37 that can be given to patients with melanoma. Researchers also want to learn if LL37 can stimulate the immune system to help control the disease.
What is the current status of trial NCT02225366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-07-08. Estimated completion is 2020-11-24.
What interventions are being tested in trial NCT02225366?
The interventions under investigation include: Photographs (OTHER), LL37 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02225366?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.